

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 15-16	Q3 14-15	% Gr y-y	YTD 15-16	YTD 14-15	% Gr y-y
Home Markets	18,390	15,987	15.0%	54,287	45,920	18.2%
US Formulations	10,717	8,959	19.6%	30,605	24,144	26.8%
India Formulations	7,130	6,418	11.1%	22,058	19,975	10.4%
Latin America Formulations	544	610	-10.8%	1,624	1,801	-9.8%
Other Markets and Businesses	5,529	5,992	-7.7%	18,031	17,691	1.9%
Europe Formulations	762	847	-10.0%	2,250	2,635	-14.6%
Emerging Markets Formulations	963	1,012	-4.8%	3,417	2,950	15.8%
Consumer Wellness	1,178	1,140	3.3%	3,401	3,317	2.5%
Animal Health & Others	785	816	-3.8%	2,355	2,393	-1.6%
APIs	838	959	-12.6%	2,725	2,853	-4.5%
JVs and Alliances	1,002	1,217	-17.7%	3,884	3,542	9.6%
Grand Total	23,920	21,979	8.8%	72,319	63,610	13.7%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 15-16	Q3 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Operating Income	865	389	122.7%	2,946	1,131	160.5%
Royalty Income	68	93	-27.4%	168	382	-55.9%
Net Gain on foreign currency transactions and translation (Refer Note below)	107	-3	3330.6%	306	0	
Others	690	299	131.0%	2,471	749	230.1%

Note : There was a net gain of Rs. 93 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q3 15-16. Thus, on aggregate level, there was a gain of Rs. 200 Mio. on operating transactions (above EBIDTA line) in Q3 15-16 vs gain of Rs. 28 Mio. in Q3 14-15. See details below for more clarity.

Rs. Mio.	Q3 15-16	Q3 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Income	254	100	154.1%	700	350	99.8%
Interest & Dividend income	157	90	75.1%	453	281	61.1%
Profit on sale of investments	12	2	631.4%	56	28	97.5%
Others	85	9	862.7%	191	41	367.2%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 15-16	Q3 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
A. On operating transactions (above EBIDTA line)	-200	-28	-628.1%	-697	-74	-840.6%
a. Included in other income	-107	3	-3330.6%	-306		
c. Included in cost of goods	-93	-47	-97.9%	-391	-90	-334.4%
d. Included in other expenses		16	-100.0%		16	-100.0%
B. On Foreign Currency Borrowings (part of interest cost)	17	25	-31.9%	60	24	148.9%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-183	-3	-7148.1%	-637	-50	-1172.0%

Details of R&D Expenses

Rs. Mio.	Q3 15-16	Q3 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Total R&D Expenses	2,368	1,883	25.7%	5,782	4,118	40.4%

Consolidated Capex for Apr-Dec 15

Rs. 4671
Mio.

R&D capex included in above for Apr-Dec 15

Rs. 197
Mio.